Credit Suisse Ag Apellis Pharmaceuticals, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 80,642 shares of APLS stock, worth $2.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,642

Previous 85,571 5.76%

Holding current value

$2.48 Million

Previous $5.12 Million 7.46%

% of portfolio

0.0%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$55.39 - $72.47 $273,017 - $357,204	-4,929 Reduced 5.76%	80,642 $4.74 Million
Q4 2023 Feb 08, 2024	SELL	$37.14 - $64.82 $53,555 - $93,470	-1,442 Reduced 1.66%	85,571 $5.12 Million
Q3 2023 Nov 13, 2023	SELL	$23.65 - $89.22 $162,475 - $612,941	-6,870 Reduced 7.32%	87,013 $3.31 Million
Q2 2023 Aug 11, 2023	BUY	$76.68 - $93.31 $761,815 - $927,034	9,935 Added 11.83%	93,883 $8.55 Million
Q1 2023 May 10, 2023	BUY	$46.59 - $66.96 $327,993 - $471,398	7,040 Added 9.15%	83,948 $5.54 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $1,643 - $2,319	38 Added 0.05%	76,908 $3.98 Million
Q3 2022 Nov 10, 2022	BUY	$44.76 - $69.66 $541,954 - $843,443	12,108 Added 18.7%	76,870 $5.25 Million
Q2 2022 Aug 12, 2022	SELL	$35.07 - $59.21 $193,025 - $325,891	-5,504 Reduced 7.83%	64,762 $2.93 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $256,517 - $391,504	7,234 Added 11.48%	70,266 $3.57 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $118,195 - $189,020	3,845 Added 6.5%	63,032 $2.98 Million
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $422,612 - $939,976	13,459 Added 29.43%	59,187 $1.95 Million
Q2 2021 Aug 16, 2021	SELL	$40.9 - $64.9 $101,432 - $160,952	-2,480 Reduced 5.14%	45,728 $2.89 Million
Q1 2021 May 14, 2021	SELL	$40.8 - $57.39 $1.73 Million - $2.43 Million	-42,362 Reduced 46.77%	48,208 $2.07 Million
Q4 2020 Feb 12, 2021	SELL	$30.79 - $57.2 $457,293 - $849,534	-14,852 Reduced 14.09%	90,570 $5.18 Million
Q3 2020 Nov 13, 2020	SELL	$25.89 - $33.65 $574,162 - $746,256	-22,177 Reduced 17.38%	105,422 $3.18 Million
Q2 2020 Aug 12, 2020	BUY	$24.8 - $38.49 $1.81 Million - $2.81 Million	73,083 Added 134.06%	127,599 $4.17 Million
Q1 2020 May 13, 2020	SELL	$17.91 - $44.33 $105,167 - $260,305	-5,872 Reduced 9.72%	54,516 $1.46 Million
Q4 2019 Feb 12, 2020	BUY	$22.1 - $30.8 $195,540 - $272,518	8,848 Added 17.17%	60,388 $1.85 Million
Q3 2019 Nov 12, 2019	BUY	$24.09 - $32.18 $549,613 - $734,186	22,815 Added 79.43%	51,540 $1.24 Million
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $87,930 - $123,785	4,885 Added 20.49%	28,725 $728,000
Q1 2019 May 14, 2019	BUY	$12.81 - $19.82 $54,878 - $84,908	4,284 Added 21.91%	23,840 $464,000
Q4 2018 Feb 13, 2019	BUY	$11.47 - $18.71 $68,670 - $112,016	5,987 Added 44.12%	19,556 $258,000
Q3 2018 Nov 13, 2018	SELL	$16.57 - $21.03 $16,006 - $20,314	-966 Reduced 6.65%	13,569 $241,000
Q2 2018 Aug 14, 2018	BUY	$19.63 - $30.0 $285,322 - $436,050	14,535 New	14,535 $320,000

Others Institutions Holding APLS

# of Institutions

309

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.38B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account